BAMF
RYTM icon

BI Asset Management Fondsmaeglerselskab’s Rhythm Pharmaceuticals RYTM Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-648
Closed -$34K – 888
2025
Q1 		$34K Buy
+648
New +$36K ﹤0.01% 876

Other funds holding RYTM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's RYTM Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2025, closing a stake of 648 shares — an estimated $34K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in RYTM in Q1 2025 and held it in 1 quarter. The position peaked at $34K in Q1 2025. 227 funds tracked by Wall St. Rank hold RYTM as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Rhythm Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 648 Rhythm Pharmaceuticals shares in Q2 2025, an estimated $34K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Rhythm Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Rhythm Pharmaceuticals position peaked at $34K in Q1 2025.
  • 227 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.